1.33 USD
▼-0.01-1.12%
盘后 1.51 0.00%
2026-09-16
市值
$69.80M
市盈率
—
EPS
-0.24
股息率
—
52 周区间
1.28 – 3.20
成交量
70.58K
Beta
0.00
目标价
8.33
52W 低 1.2852W 高 3.20
价格走势
公司简介
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.